-
May 22, 2018
Aileron Therapeutics Announces Publication of ALRN-6924 Nonclinical Data in T-cell Lymphomas by Researchers at Dana-Farber Cancer Institute
-
May 15, 2018
Aileron Therapeutics Announces Changes to Management
-
May 9, 2018
Aileron Therapeutics Reports First Quarter 2018 Financial Results
-
April 11, 2018
Aileron Therapeutics Announces Publication by Researchers at Albert Einstein College of Medicine of ALRN-6924 Nonclinical Data in Acute Myeloid Leukemia
-
April 2, 2018
Aileron Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results
-
March 28, 2018
Aileron Therapeutics Announces Expansion of Scientific Advisory Board
-
March 19, 2018
Aileron Therapeutics Appoints Jeffrey A. Bailey to its Board of Directors
-
December 11, 2017
Aileron Therapeutics Presents New Data on ALRN-6924 in Oral Presentations at 2017 American Society of Hematology Meeting
-
November 9, 2017
Aileron Therapeutics Reports Third Quarter 2017 Financial Results
-
November 1, 2017
Aileron Therapeutics Announces Oral Presentations on Lead Product Candidate ALRN-6924 at the 59th American Society of Hematology Annual Meeting